Скачать с ютуб Mandeep Mehra, ESC 2022: HeartMate 3™ LVAD for heart failure, 2- and 5-year results of MOMENTUM 3 в хорошем качестве

Mandeep Mehra, ESC 2022: HeartMate 3™ LVAD for heart failure, 2- and 5-year results of MOMENTUM 3

Following its positive 2-year results, the MOMENTUM 3 study in patients with heart failure was extended to assess 5-year outcomes of the HeartMate 3™ left ventricular assist device. In this touchCARDIO interview, we speak with Dr Mandeep Mehra (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) to discuss the MOMENTUM 3 study and its findings at both 2 and 5 years. The abstract entitled ‘5-year Survival with LVAD Therapy in MOMENTUM 3’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022. Questions: 1. What were the aims, design and eligibility criteria of the MOMENTUM 3 study? (0:21) 2. were the study efficacy and outcomes and how well were they achieved at 2 years? (5:19) 3. What have been the 5-year findings, and have any late complications emerged? (7:37) Disclosures: Mandeep Mehra is a consultant for Abbott, Janssen, Mesoblast, Medtronic, Natera and Paragonix and is on the advisory board for FineHeart, Leviticus, NupulseCV and Transmedics. Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby. Filmed as a highlight of ESC 2022 (https://www.touchcardio.com/conferenc...) Access more content on: Devices here: https://www.touchcardio.com/specialit... Heart Failure here: https://www.touchcardio.com/specialit... Additional Resources: Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. JAMA. 2022; doi: 10.1001/jama.2022.16197.